8.1 Status Epilepticus & Acute Encephalopathy

8.1 Status Epilepticus & Acute Encephalopathy

Clinical Scenario: A 58-year-old male with alcohol use disorder and traumatic brain injury presents to the ICU with continuous generalized convulsions lasting 14 minutes. Vital signs: BP 174/98 mmHg, HR 136 bpm, RR 28 breaths/min, SpO2 88% on room air, and temperature 38.6°C. Fingerstick glucose is 118 mg/dL. He received IV lorazepam 2 mg from EMS 8 minutes ago, but convulsions continue unabated without recovery of consciousness.

Operational Definitions: The $t_1$ and $t_2$ Paradigms

Status epilepticus (SE) represents a neurological emergency resulting from failure of seizure termination mechanisms:

• Time Point 1 ($t_1$ = 5 minutes): In generalized convulsive status epilepticus (GCSE), $t_1$ defines when a seizure is abnormally prolonged and unlikely to cease spontaneously ($\ge 5$ minutes of continuous seizure or $\ge 2$ discrete seizures without interval recovery). This mandates immediate emergent pharmacotherapy.
• Time Point 2 ($t_2$ = 30 minutes): For tonic-clonic SE, this is the estimated point beyond which long-term consequences, including neuronal injury, may occur. It is not an exact irreversible-injury threshold; risk depends on seizure type, duration and cause.

Benzodiazepines become less reliable as seizures continue. Give an adequate initial dose promptly and escalate rapidly when seizure activity persists.

The AES / NCS Stepwise Pharmacotherapy Algorithm

The AES framework begins with 0–5-minute stabilization: airway/oxygenation, monitoring, IV access and glucose assessment. Continue resuscitation throughout treatment. Phase times organize care; do not delay escalation after adequate therapy fails:

Phase 1: Initial Therapy (5–20 Minutes)

Give IV lorazepam 0.1 mg/kg up to 4 mg, over about 2 minutes. If convulsions continue, repeat the IV dose once per protocol while preparing second-line therapy. If IV access is delayed, give IM midazolam as a single initial dose (10 mg for patients over 40 kg).

Phase 2: Second Therapy (20–40 Minutes)

If seizures persist after adequate benzodiazepine therapy, promptly load a second-line IV antiseizure drug. In ESETT, about half of patients responded to each of the following agents:

• Levetiracetam (Keppra): 60 mg/kg IV (max 4,500 mg) over 10 minutes. Binds SV2A; no hepatic CYP interactions, but requires renal adjustment.
• Fosphenytoin (Cerebyx): 20 mg PE/kg IV (max 1,500 mg PE) at $\le 150$ mg PE/min. Water-soluble phenytoin prodrug. Monitor ECG and blood pressure because hypotension and arrhythmias can still occur.
• Valproate Sodium (Depacon): 40 mg/kg IV (max 3,000 mg) over 10 minutes. Contraindicated in liver failure, urea cycle disorders, and mitochondrial cytopathies.
• Lacosamide (Vimpat): A specialist may select it as an alternative or adjunct. Check cardiac conduction and follow the infusion protocol.

Phase 3: Refractory Status Epilepticus (RSE) & Continuous Infusions

RSE is defined as ongoing seizure activity despite adequate benzodiazepine and second-line ASM therapy (~30% of cases).

• Critical Care Management: When escalating to continuous anesthetic therapy, secure the airway and closely monitor hemodynamics. Treat anesthesia-related hypotension promptly.
• Anesthetic Infusions:
  • Propofol: Load 1–2 mg/kg, then infuse 30–200 mcg/kg/min. Monitor for Propofol Infusion Syndrome (PRIS): metabolic acidosis, rhabdomyolysis, hyperkalemia, hepatomegaly, and biventricular failure. Use the lowest effective dose. Prolonged high-dose therapy increases PRIS risk, especially above 5 mg/kg/hr for more than 48 hours. Stop propofol promptly if PRIS is suspected.
  • Midazolam: Load 0.2 mg/kg, then infuse 0.05–2.0 mg/kg/hr (tachyphylaxis common).
  • Ketamine: NMDA antagonist used as a specialist-directed option in refractory seizures. Dosing and hemodynamic monitoring follow the neurocritical care protocol.
• cEEG Endpoints: Start continuous EEG as soon as possible. Target electrographic seizure cessation. The team may use burst suppression in selected cases. A common approach is to maintain electrographic control for 24–48 hours before a monitored taper.
• Super-Refractory Status (SRSE): Seizures continuing or recurring despite $\ge 24$ hours of adequate anesthetic therapy require specialist reassessment and cause-directed care. Selected rescue options include ketogenic diet or inhaled anesthetics; consider immunotherapy when immune-mediated disease is suspected.

Non-Convulsive Status Epilepticus (NCSE) in the ICU

NCSE is an important cause of unexplained coma or persistent altered consciousness after convulsions; frequency varies by population and EEG selection. Clues include rhythmic blinking, gaze deviation and fluctuating responsiveness, but motor signs may be absent. Obtain urgent EEG/cEEG.

Under the Salzburg criteria, patients without pre-existing epileptic encephalopathy may qualify with epileptiform discharges >2.5 Hz. Slower discharges (≤2.5 Hz) or rhythmic delta/theta activity (>0.5 Hz) require typical evolution, subtle clinical ictal signs, or both EEG and clinical improvement after IV antiseizure medication. EEG improvement alone supports possible NCSE, not definite NCSE. Interpret qualifying patterns with duration, baseline EEG and the clinical context.

Infectious Meningitis and Encephalitis

Fever with headache, neck stiffness, altered consciousness, seizures or focal deficits requires urgent consideration of CNS infection. Obtain blood cultures and perform lumbar puncture promptly when safe; suspected mass effect or other contraindications require assessment before LP. Do not delay empiric treatment while awaiting CT or LP. For suspected community-acquired bacterial meningitis in a U.S. adult, start IV meningitis-dose ceftriaxone or cefotaxime plus vancomycin. Add ampicillin for Listeria risk, such as older age or immunocompromise. Give adjunctive dexamethasone with the first antibiotic dose when indicated. Suspected encephalitis also warrants immediate IV acyclovir pending HSV testing, with renal dose adjustment. Send CSF cell count, glucose, protein, culture and appropriate PCR tests; narrow therapy as results clarify the cause.

Acute Toxic-Metabolic Encephalopathies

• Hepatic Encephalopathy (HE): Ammonia neurotoxicity causes astrocyte swelling and increased GABAergic tone. Start lactulose, then titrate maintenance to 2–3 soft stools daily. Add rifaximin (550 mg PO twice daily) when indicated, particularly to prevent recurrence after repeated overt episodes. Correct triggers: GI bleeding, SBP, hypokalemia, and dehydration.
• Uremic Encephalopathy: Retention of guanidino toxins produces asterixis, myoclonus, and seizures; resolved with urgent hemodialysis or continuous renal replacement therapy (CRRT).
• Wernicke's Encephalopathy: Acute thiamine (Vitamin B1) deficiency impairs pyruvate dehydrogenase and transketolase, causing mammillary body and thalamic necrosis. Classic triad: encephalopathy/confusion, gait ataxia, and ophthalmoplegia/nystagmus. Treat with thiamine 500 mg IV q8h for 3 days, then 250 mg IV daily for 3 to 5 days.